FTSE MIB
28.222,39 -20,87 (-0,07%) Dow Jones
33.507,50 -158,80 (-0,47%) Nasdaq
13.219,32 +18,02 (+0,14%) Nikkei 225
31.759,88 -97,72 (-0,31%) Petrolio
91,37 +0,58 (+0,64%) Bitcoin EUR
26.795,89 +967,17 (+3,74%)
Sarepta Therapeutics, Inc. (SRPT)
Preborsa:
| Chiusura precedente | 123,59 |
| Aperto | 124,00 |
| Denaro | 110,00 x 800 |
| Lettera | 123,42 x 1300 |
| Min-Max giorno | 120,84 - 124,10 |
| Intervallo di 52 settimane | 100,15 - 159,89 |
| Volume | |
| Media Volume | 897.992 |
| Capitalizzazione | 11,307B |
| Beta (5 anni mensile) | 0,94 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -10,10 |
| Prossima data utili | 31 ott 2023 - 06 nov 2023 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 180,94 |
GlobeNewswireSarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023. The equity awards were approved in accordance with Nasdaq Listing
- GlobeNewswire
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
- The Company expects to exceed 2022 full-year guidance for net product revenues - Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million and $843.3 million, respectively - Preliminary year-end 2022 cash balance of approximately $2.0 billion CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and
- GlobeNewswire
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 9, 2023 at 1:30 p.m. E.T. / 10:30 a.m. P.T. Following the presentation there will be a Q&A session starting at 1:50 p.m. E.T. / 10:50 a.m. P.T. The presentation will be webcast live under the E
